Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
wPRMFunNeFzFzsPF
